P Dee Stephenson, MD, FACS2019 OIS

Confidential

Atia Vision: Company Status

2

2001 2011 2012 2016 2017

Coronary Artery

Disease

Structural Heart

DiseaseHypertension Atrial Fibrillation Atrial Fibrillation

Acquired by

Boston Scientific

Acquired by

Boston Scientific

Acquired by

Covidien

Acquired by

Abbott/Terumo

Acquired by

Boston Scientific

A Shifamed Portfolio Company

Highly focused medical innovation hub

with a solid track record of success

Early stage start-up in the ophthalmology space

Initiated clinical studies

Recently closed $20M financing

Confidential

Evolution of Accommodating IOLs

3

1st Generation

Single Optic

Axial Lens

Displacement

Limited

accommodative

response

2rd Generation

Dual Optic

Axial Lens

Displacement

Difficult in surgery,

Did not meet

accommodative

endpoints

3rd Generation

Optic fluid filled,

Shape changing

single optic

Unpredictable refractive

and accommodative

outcomes,

higher amplitude of

accommodation

“Holy Grail”

Truly Accommodating

Lens

Predictable

accommodative &

refractive outcomes

Next Frontier

Confidential

Atia Vision: Next Frontier Premium IOL

4

SHAPE CHANGING ACCOMMODATING ENGINE

• Hydraulic multiplier design, mimics the natural dynamic accommodation mechanism of the eye

• Maintains direct contact with open capsular bag for efficient energy transfer from ciliary muscle to the optic

EXCHANGEABLE FRONT OPTIC

• Stable optic for refractive predictability

• Addresses each patient’s prescription needs - available in multiple powers and degrees of toricity

• Opportunity for future upgrades as optic technology advances

MODULAR DUAL LENS DESIGN

Aims to restore the full range of functional vision

Correction of short and long-term refractive issues

Designed to prevent visual disturbances & artifacts

Easily exchangeable front optic

Confidential5

CLINICAL UPDATE

6

Confidential

Clinical Summary to Date:

7

Credit to Prof. Igor Solomatin and Dr. Andrei Solomatinhttps://drsolomatinisilmakeskus.ee/

Started FIH studies with promisingpreliminary data

No significant product-related adverse events

Accommodative response

Both subjective and objective measurements showing accommodation

Confidential8

Subject 001: UBM Imaging

30 µm cavity height difference observed in Base Component’s fluid chamber

Equates to 1.5D power shift

POST OP: ASSESSMENT OF FIT AND ACCOMODATIVE RESPONSEPRE OP: GAUGE BIOMETRY AND CAPSULE SIZE

Confidential

DCVA – 0.0 LogMAR (20/20)

DCIVA – 0.1 LogMAR (20/25)

DCNVA - 0.1 LogMAR (20/25)

9

Subject 001: Subjective Testing Corroborate UBM Result

Control data: N=25, J. Alio, et. al., Visual Outcomes and

Accommodative…, AJO, Vol 164, April 2016, Pgs 37-48

Acuity Test Defocus Test

Confidential

Atia Vision Summary

10

L A R G E M A R K E T O P P O R T U N I T Y

• 3.6M cataract procedures performed annually in the US, over 20M worldwide1

• Global IOL market expected to reach $5.5B by 20222

• Potential expansion into larger presbyopia market

D I F F E R E N T I AT E D S O L U T I O N

• Simplicity of stable, predictable front optic exchange allows for refining both initial and long-term refractive outcomes with future novel optics technology

• Shape changing dynamic accommodation with efficient energy transfer from the ciliary muscles to the optic, not between components

• Completed biocompatibility and preclinical tests for FIH studies

• Completed design verification testing

• Started FIH cases

M I L E S T O N E SE F F I C I E N T

O P E R AT I O N S

• Leverage learnings from 1st

generation devices

• Proven development process and streamlined resources to deliver high-impact results

• Recently closed on $20M financing

1. https://www.reviewofophthalmology.com/article/thoughts-on--cataract-surgery-20152. Market Scope 2017 Global IOL Market Report

APPENDIX

11